Market Overview

UPDATE: Goldman Sachs Downgrades Mettler Toledo International to Neutral on Continued Uncertainty

Related MTD
Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies
Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies

In a report published Thursday, Goldman Sachs analyst Isaac Ro downgraded the rating on Mettler Toledo International (NYSE: MTD) from Buy to Neutral, but reiterated the $226.00 price target.

In the report, Ro noted, “We downgrade shares of Mettler Toledo from Buy to Neutral. Since adding MTD to the Buy List on August 5, 2011, shares are +55% versus the S&P +32%. Over the past 12 months, MTD is +23% vs. S&P +17%. Our Buy thesis was predicated upon a strong management franchise that offered high exposure to emerging markets, opportunity for share gains, and minimal exposure to academic funding pressures. While we continue to appreciate industry-best management quality, our current Neutral rating is based on continued macroeconomic uncertainty in the emerging markets (chiefly China), less favorable risk-reward, and fair valuation in the backdrop of current growth environment. We make no changes to our estimates or price target.”

Mettler Toledo International closed on Wednesday at $213.12.

Latest Ratings for MTD

Jan 2017Deutsche BankInitiates Coverage OnHold
Jan 2017Deutsche BankInitiates Coverage OnHold
Aug 2016Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for MTD
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Analyst Ratings


Related Articles (MTD)

View Comments and Join the Discussion!